BAY 2666605（Cat No.:I043969）is a selective, oral inhibitor of the protein kinase CK2 (casein kinase 2), which is involved in various cellular processes, including cell cycle regulation, apoptosis, and DNA repair. By inhibiting CK2, BAY 2666605 disrupts cancer cell proliferation and survival, making it a promising therapeutic candidate for cancer treatment. It has demonstrated significant preclinical efficacy in several tumor models, including solid tumors and hematological malignancies. BAY 2666605 is currently being investigated in clinical trials for its potential as a targeted anticancer agent, with an emphasis on overcoming treatment resistance.